Search clinical trials for: Cystic fibrosis transmembrane conductance regulator modulator therapy

Total 76187 results

National Cancer Institute (NCI)

Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma

United States
Universitair Ziekenhuis Brussel

Not yet recruiting

Real-world Efficacy and Safety of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy in Adult Patients With Cystic Fibrosis (CF)

Cystic Fibrosis
University of British Columbia

Recruiting

Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF (Can-IMPACT CF)

Cystic Fibrosis

Canada
Children's Hospital Medical Center, Cincinnati

Active, not recruiting

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

Cystic Fibrosis

United States
Hospices Civils de Lyon

Recruiting

Circadian Rhythm Disorders in Children With Cystic Fibrosis Under CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Modulators (CHRONO-MUCO)

Cystic Fibrosis

France
Children's Hospital of Philadelphia
Vertex Pharmaceuticals Incorporated

Completed

Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Cystic Fibrosis

United States, Australia, Canada, Germany, Switzerland, Israel, Netherlands, Belgium, Italy, United Kingdom, France
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Cystic Fibrosis

United States, Canada, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Cystic Fibrosis

United States, United Kingdom, Canada
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) (KONDUCT)

Cystic Fibrosis

United States, United Kingdom
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation (KONNECTION)

Cystic Fibrosis

United States, France, Belgium
University Hospitals Cleveland Medical Center

Recruiting

Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients

Cystic Fibrosis

United States
Charite University, Berlin, Germany
Hannover Medical School; Heidelberg University; University of Giessen

Recruiting

Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators (Modulate-CF)

Cystic Fibrosis

Germany
Cliniques universitaires Saint-Luc- Université...
Université de Liège

Recruiting

New Markers of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Sweat

Cystic Fibrosis | Biomarkers

Belgium
Qanatpharma Canada LTD

Completed

Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated Tablets

Healthy Volunteer

Canada
Ciusss de L'Est de l'Île de Montréal
Juvenile Diabetes Research Foundation; Institut de Recherches Cliniques de...

Completed

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Exocrine Pancreatic Dysfunction in Type 1 Diabetes

Type 1 Diabetes | Exocrine Pancreatic Insufficiency

Canada
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

Cystic Fibrosis

United States, Belgium, Germany, France, United Kingdom, Ireland, Romania
Insmed Incorporated

Completed

Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Cystic Fibrosis

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Serbia, Denmark, Greece, Netherlands, Hungary, Ireland, Slovakia, Canada, Italy, Austria
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

Cystic Fibrosis

United States, Belgium, Canada, Netherlands, Germany
Assistance Publique - Hôpitaux de Paris

Terminated

Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients

Cystic Fibrosis

France
CF Therapeutics Development Network Coordinating...
Cystic Fibrosis Foundation

Completed

Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects

Cystic Fibrosis

United States
University of Alabama at Birmingham
National Institutes of Health (NIH)

Completed

Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators

Cystic Fibrosis

United States
University of Alabama at Birmingham
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis

Cystic Fibrosis
Actelion

Terminated

Miglustat / OGT 918 in the Treatment of Cystic Fibrosis

Cystic Fibrosis

Spain
National Center for Research Resources (NCRR)
University of North Carolina

Completed

Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis

Cystic Fibrosis
University of Kansas Medical Center

Recruiting

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Cystic Fibrosis

United States
Universidad Politecnica de Madrid
Hospital Infantil Universitario Niño Jesús, Madrid, Spain; Hospital Universitario... and other collaborators

Recruiting

Exercise in People With Cystic Fibrosis on CFTR Modulator Therapy (FIQMODE)

Cystic Fibrosis

Spain
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis Foundation

Recruiting

Health Outcomes of Parents With Cystic Fibrosis-Aim 2 (HOPeCF)

Cystic Fibrosis | Parenthood Status

United States
Dartmouth-Hitchcock Medical Center

Recruiting

Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

Cystic Fibrosis

United States
University of Portsmouth
University Hospital Southampton NHS Foundation Trust

Recruiting

Sweat Response, Sweat Composition and Thermoregulatory Response to Exercise in Heat in Adults With Cystic Fibrosis on Modulator Therapy. (Sweat-CF)

Cystic Fibrosis

United Kingdom
University of Portsmouth
University Hospital Southampton NHS Foundation Trust

Recruiting

Fitness, Body Composition, Physical Activity and Sleep Patterns in People With Cystic Fibrosis on Modulator Therapy. (Understand-CF)

Cystic Fibrosis

United Kingdom
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis Foundation

Recruiting

Health Outcomes of Parents With Cystic Fibrosis (HOPeCF)

Cystic Fibrosis | Parenthood Status

United States
Vertex Pharmaceuticals Incorporated
Moderna, Inc

Recruiting

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, United Kingdom, Australia, Canada
Hospices Civils de Lyon

Not yet recruiting

Effectiveness of CFTR Modulators According to Co-therapy (MODUCO)

Cystic Fibrosis
University of Erlangen-Nürnberg Medical School

Recruiting

Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor

Cystic Fibrosis

Germany
Sheffield Teaching Hospitals NHS Foundation Trust

Recruiting

Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis

Cystic Fibrosis

United Kingdom
University of Missouri-Columbia

Recruiting

Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) (SPACE-CF)

Cystic Fibrosis | Mucociliary Clearance Defect

United States
Sonya Heltshe
University of Alabama at Birmingham; University of Washington; Cystic Fibrosis...

Recruiting

Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children (BEGIN)

Cystic Fibrosis

United States
Jennifer Taylor-Cousar
Cystic Fibrosis Foundation

Recruiting

Impact of Triple Combination CFTR Therapy on Sinus Disease.

Cystic Fibrosis

United States
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom, Canada, Australia, France, Germany, Italy, Czechia, Austria, Sweden, Greece
Indiana University
Cystic Fibrosis Foundation; Folia Health

Completed

HERO-2: Home-Reported Outcomes With CFTR Modulator Therapy

Cystic Fibrosis

United States
Royal College of Surgeons, Ireland
The Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaborators

Active, not recruiting

Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) (RECOVER)

Cystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver Disease

United Kingdom, Ireland
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study (SIMPLIFY-DN)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Nicole Hamblett
Cystic Fibrosis Foundation

Active, not recruiting

The PROMISE Pediatric Study 6 to 11 Years Old

Cystic Fibrosis | Cystic Fibrosis in Children

United States
Nicole Hamblett
Cystic Fibrosis Foundation

Active, not recruiting

A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (PROMISE)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, United Kingdom, New Zealand, Israel, Australia, Ireland, Germany, Sweden, Czechia, Portugal, Hungary

Search clinical trials for: Cystic fibrosis transmembrane conductance regulator modulator therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations